Trexquant Investment LP Reduces Position in Bioventus Inc. (NYSE:BVS)

Trexquant Investment LP decreased its stake in Bioventus Inc. (NYSE:BVS - Free Report) by 56.8% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 44,471 shares of the company's stock after selling 58,493 shares during the quarter. Trexquant Investment LP owned approximately 0.05% of Bioventus worth $467,000 at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. Plato Investment Management Ltd acquired a new position in Bioventus in the fourth quarter valued at about $38,000. KLP Kapitalforvaltning AS bought a new stake in shares of Bioventus during the 4th quarter valued at $75,000. Quantbot Technologies LP bought a new position in shares of Bioventus in the 4th quarter worth $103,000. Arizona State Retirement System acquired a new position in Bioventus in the fourth quarter valued at about $109,000. Finally, HighTower Advisors LLC grew its position in shares of Bioventus by 11.3% during the 4th quarter. HighTower Advisors LLC now owns 13,617 shares of the company's stock worth $143,000 after buying an additional 1,380 shares during the period. 62.94% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Separately, Canaccord Genuity Group reaffirmed a "buy" rating and issued a $15.00 target price on shares of Bioventus in a research report on Monday, March 17th.

Insider Transactions at Bioventus

In other news, SVP Anthony D'adamio sold 4,380 shares of the stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $10.19, for a total transaction of $44,632.20. Following the transaction, the senior vice president now directly owns 118,178 shares in the company, valued at approximately $1,204,233.82. This represents a 3.57 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Mark Leonard Singleton sold 5,479 shares of the stock in a transaction dated Monday, March 24th. The stock was sold at an average price of $9.79, for a total transaction of $53,639.41. Following the sale, the chief financial officer now owns 131,963 shares of the company's stock, valued at approximately $1,291,917.77. This represents a 3.99 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 24,208 shares of company stock worth $226,138 in the last quarter. Insiders own 32.90% of the company's stock.

Bioventus Trading Up 0.5 %

BVS traded up $0.04 during trading on Friday, reaching $7.82. 323,591 shares of the company's stock were exchanged, compared to its average volume of 443,931. Bioventus Inc. has a one year low of $3.90 and a one year high of $14.38. The firm has a fifty day moving average price of $9.35 and a two-hundred day moving average price of $10.63. The company has a current ratio of 1.41, a quick ratio of 0.99 and a debt-to-equity ratio of 1.85. The stock has a market capitalization of $640.80 million, a PE ratio of -12.82 and a beta of 0.92.

Bioventus Company Profile

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.